Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects

Amyotrophic Lateral Sclerosis

Volumn 8, Issue 6, 2007, Pages 373-379

  Ranganathan, Srikanth ^a   Nicholl, Georgina C B ^b   Henry, Sarah ^b   Lutka, Fran ^b   Sathanoori, Ramasri ^c   Lacomis, David ^b   Bowser, Robert ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Lofstrand Labs Limited   (United States)

Author keywords

Biomarkers; Cerebrospinal fluid; Mass spectrometry; Proteomics

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CYSTATIN C; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; PREALBUMIN; PROTEIN VGF; PROTEOME; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; SYMPTOMATOLOGY;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; POSTMORTEM CHANGES; PROTEOME; PROTEOMICS;

EID: 36148951552     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/17482960701549681     Document Type: Article

References (18)

1. Katz, R. (2004) Biomarkers and surrogate markers: An FDA perspective. NeuroRx, 1, pp. 189-195.
2. Coon, K. D., Dunckley, T. and Stephan, D. A. (2004) Biomarker identification in neurologic diseases: Improving diagnostics and therapeutics. Expert Rev Mol Diagn, 4, pp. 361-375.
3. Bowser, R., Cudkowicz, M. and Kaddurah-Daouk, R. (2006) Biomarkers for amyotrophic lateral sclerosis. Expert Rev Mol Diagn, 6, pp. 387-398.
4. Miller, D. H. (2004) Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis. NeuroRx, 1, pp. 284-294.
5. Puchades, M., Hansson, S. F., Nilsson, C. L., Andreasen, N., Blennow, K. and Davidsson, P. (2003) Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Mol Brain Res, 118, pp. 140-146.
6. Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O., Corthals, G. and Burkhard, P. (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics, 3, pp. 1486-1494.
7. Ranganathan, S., Williams, E., Ganchev, P., Gopalakrishnan, V., Lacomis, D. and Urbinelli, L. (2005) Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem, 95, pp. 1461-1471.
8. Ferrante, R. J., Browne, S. E., Shinobu, L. A., Bowling, A. C., Baik, M. J. and MacGarvey, U. (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem, 69, pp. 2064-2074.
9. Quinn, J. F., Montine, K. S., Moore, M., Morrow, J. D., Kaye, J. A. and Montine, T. J. (2004) Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimer's Dis, 6, pp. 93-97.
10. Brettschneider, J., Petzold, A., Submuth, S. D., Ludolph, A. C. and Tumani, H. (2006) Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology, 66, pp. 852-856.
11. Lescuyer, P., Allard, L., Zimmerman-Ivol, C. G., Burgess, J. A., Hughes-Frutiger, S. and Burkhard, P. R. (2004) Identification of post mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration. Proteomics, 4, pp. 2234-2241.
12. Finehout, E. J., Franck, Z., Relkin, N. and Lee, K. H. (2006) Proteomic analysis of cerebrospinal fluid changes related to post mortem interval. Clin Chem, 52, pp. 1906-1913.
13. You, J-S., Gelfanova, V., Knierman, M. D., Witzmann, F. A., Wang, M. and Hale, J. E. (2005) The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics, 5, pp. 290-296.
14. Ranganathan, S., Polshyna, A., Nicholl, G., Lyons-Weiler, J. and Bowser, R. (2006) Assessment of protein stability in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry protein profiling. Clin Proteomics, 2, pp. 91-102.
15. Brooks, B. R., Miller, R. G., Swash, M. and Munsat, T. L. (2000) El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lat Scler, 1, pp. 293-299.
16. Pasinetti, G. M., Ungar, L. H., Lange, D. J., Yemul, S., Deng, H. and Yuan, X. (2006) Identification of potential CSF biomarkers in ALS. Neurology, 66, pp. 1218-1222.
17. Serot, J. M., Christmann, D., Dubost, T. and Couturier, M. (1997) Cerebrospinal fluid transthyretin: Aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry, 63, pp. 506-508.
18. Biroccio, A., Boccio, P. del, Panella, M., Bernardini, S., Dillio, C. and Gambi, D. (2006) Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid. Proteomics, 6, pp. 2305-2313.